Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Government Rejects WHO Definition Of Counterfeit Drugs; Stresses Need For Harmonization Among Member States

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The Indian government may have succeeded in blocking a move to redefine "counterfeit drugs" by the International Medical Products Anti-Counterfeiting Taskforce - an arm of the World Health Organization. In its definition, IMPACT defined a medical product as counterfeit "when there is a false representation in relation to its identity, history or source.

You may also be interested in...



India Says Counterfeit Drugs Should Be Handled By WTO - Not WHO

MUMBAI - Years of strong opposition from the Indian government, bolstered by recent support in that effort by some Latin American, African and South-East Asian countries, has exerted pressure on the World Health Assembly to establish a working group to handle the controversy surrounding the definition of "substandard" and "counterfeit" drugs

India Says Counterfeit Drugs Should Be Handled By WTO - Not WHO

MUMBAI - Years of strong opposition from the Indian government, bolstered by recent support in that effort by some Latin American, African and South-East Asian countries, has exerted pressure on the World Health Assembly to establish a working group to handle the controversy surrounding the definition of "substandard" and "counterfeit" drugs

Roche India's Efforts To Curb Fake Drugs Gain Popularity

NEW DELHI - While the global pharmaceutical industry struggles to arrive at a consensus on a new definition of counterfeit drugs, pharmaceutical company Roche India has introduced a cost-effective technology to tackle the problem called 'mass serialisation' that is fast gaining popularity among customers, say company officials

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel